Search Results
Your search for ,aGe matches 8736 pages
Showing 2751 - 2800Meditation and Education Interventions May Improve Depressive Symptoms in Young Breast Cancer Survivors
A diagnosis of breast cancer and subsequent treatment may increase the risk of depression, especially among younger women with breast cancer. A new study showed that behavioral interventions—specifically mindfulness meditation and survivorship education classes—may reduce depressive symptoms, as...
Novel Insights Into Multiple Myeloma
“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for...
COVID Virus–Specific T Cells: Potential Treatment of Severe COVID-19 Infection Under Study
It may be possible to exploit T cells from healthy volunteers who have recovered from COVID-19 as a treatment for this viral infection. Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine have designed an off-the-shelf COVID virus–specific T-cell product (called...
Study Examines Pregnancy Outcomes in Breast Cancer Survivors
Breast cancer survivors of child-bearing age appear to have a more difficult time becoming pregnant than the general population, and when they do become pregnant, they have a higher risk of preterm labor and need for cesarean section. Fortunately, most women deliver healthy babies, but they are...
Can a High-Carbohydrate Diet Increase the Risk for Breast Cancer?
A growing body of evidence is showing a strong association between diet and breast cancer risk and survival, particularly high glycemic load and sugar intake. Two large population studies at the 2020 San Antonio Breast Cancer Symposium supported these observations.1,2 Findings from the Nurses’...
Stereotactic Ablative Body Radiotherapy in Extracranial Oligometastatic Cancers
In a registry-based observational study reported in The Lancet Oncology, Anastasia Chalkidou, PhD, and colleagues found that stereotactic ablative body radiotherapy (SABR) was associated with high overall survival and low rates of toxicity in patients with extracranial oligometastatic cancers. The...
Improvement in Patient-Reported Outcomes After Stopping Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
In the prospective LAST study reported in JAMA Oncology, Ehab Atallah, MD, and Kathryn Flynn, PhD, of the Medical College of Wisconsin, Milwaukee, and colleagues, found that stopping tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) was associated with the...
Increase in Metastatic Prostate Cancer Diagnoses in the United States After Reduction in PSA Screening
Reduced levels of screening for prostate cancer using prostate-specific antigen (PSA) testing correspond with recent increases in the diagnosis of metastatic disease in the United States, according to a study that will be presented by Vidit Sharma, MD, and colleagues at the 2021 Genitourinary...
Understanding Patients’ Needs and Preferences: Cancer Care Stakeholders Explore Barriers and Best Practices
The keynote speaker did not mince words. “I tell everyone, do not use the term age-appropriate therapy,” said Jan White, a cancer survivor and patient advocate who described her own experience with stage IV non-Hodgkin lymphoma. “Patients with cancer,” she said, “are more than their age, gender,...
MAPK/ERK Inhibitor Mirdametinib in Adolescents and Adult Patients With NF1-Related Plexiform Neurofibromas
In the Neurofibromatosis Clinical Trials Consortium phase II NF106 trial, reported in the Journal of Clinical Oncology, Weiss et al found evidence of activity of the oral MAPK/ERK kinase inhibitor mirdametinib in adolescents and adult patients with neurofibromatosis type 1 (NF1)-related plexiform...
Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79
Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature. “At St. Jude, the nature of our work requires a bold, ambitious...
Breast Cancer–Specific Mortality by Race/Ethnicity and 21-Gene Recurrence Scores
In a U.S. population–based cohort study reported in JAMA Oncology, Hoskins et al found that among patients with estrogen receptor–positive breast cancer, Black women were more likely than White women to have a high Oncotype DX 21-gene recurrence score. Researchers also found that breast...
Mental Health–Related Symptoms Among Cancer Survivors During the First Wave of the COVID-19 Pandemic in the United States
In an analysis from the COVID-19 Impact Survey reported in JCO Oncology Practice, Islam et al found that U.S. adult cancer survivors were more likely to report mental health–related symptoms vs adults without cancer during the first wave of the COVID-19 pandemic. Study Details Data for the analysis ...
Delay in Time Between Abnormal At-Home Screening and Colonoscopy May Increase Colorectal Cancer Risk
At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening. Usage of these tests has increased during the COVID-19 pandemic as patients try to avoid clinical visits. However, effectiveness of these screening tools, along with...
HIC Assays May Aid in Predicting Response to Immunotherapy Among Patients With NSCLC
Using a host immune classifier (HIC) test for patients with non–small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented by Akerley et al at the International Association for the Study of Lung Cancer (IASLC) 2020 World...
Patients With Lymphoma Receiving B-Cell–Depleting Therapies May Be at Greater Risk for Persistent COVID-19 Infection
B-cell–depleting immunotherapy may cause B-cell aplasia and impair the body’s immune response. A retrospective, multicentric French study of patients with lymphoma and persistent COVID-19 infection has found that those treated with B-cell–depleting therapies within the previous 12 months had nearly ...
Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection
Due to concerns that patients with cancer may be at higher risk for contracting the coronavirus—and may have more severe complications if infected—during the COVID-19 pandemic, hospitals and clinical practices have changed protocols to routine cancer care to reduce patients’ exposure to the virus....
Socially Distant Drive-by FluFIT Clinics May Increase Colorectal Cancer Screening Rates Among Black Patients During the COVID-19 Pandemic
Administering colorectal cancer screening kits through a socially distant drive-by flu vaccination clinic increased access to colorectal cancer screening among Black Americans, according to results presented by Washington et al at the AACR Virtual Meeting: COVID-19 and Cancer (Abstract S02-04)....
Study Finds More Than Half of U.S. Cancer Survivors Have Underlying Medical Conditions Associated With Severe COVID-19 Illness
A recent study has found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness. The report, published by Jiang et al in JNCI: The Journal of the National Cancer Institute, suggested that...
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
Germline Whole-Exome Sequencing Reveals the Potential Role of Hereditary Predisposition and Therapeutic Implications in SCLC
A study presented by Nobuyuki Takahashi, MD, of the Center for Cancer Research at the National Cancer Institute, at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore (Abstract OA11.05) demonstrated that there may be an inherited ...
Taiwanese TALENT Study Supports Effectiveness of Low-Dose CT for Lung Cancer in Certain Populations
A study presented by researchers with the Ministry of Health and Welfare in Taiwan confirmed low-dose computed tomography (CT) screening may be feasible in a predefined, never-smoking, high-risk population. The research was presented at the International Association for the Study of Lung Cancer...
Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes: Association With Disease Risk
In a study reported in The New England Journal of Medicine, members of the international Breast Cancer Association Consortium (BCAC) identified the risk of disease associated with germline protein-truncating and rare missense variants of putative susceptibility genes in a large population of breast ...
New Burkitt Lymphoma International Prognostic Index
As reported by Olszewski et al in the Journal of Clinical Oncology, members of The Burkitt Lymphoma International Prognostic Index Consortium have developed an index—the Burkitt Lymphoma International Prognostic Index (BL-IPI)—that provides “robust discrimination of survival” among adult patients...
Emil J Freireich, MD, Dies at 93
Emil J Freireich, MD, an oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized as a founding father of modern clinical cancer research, passed away on February 1. He was 93. Dr. Freireich was a faculty member at The University of Texas MD Anderson Cancer ...
Featured Presentations at WCLC Focus on Disparities in Patients With Lung Cancer
At a press briefing held by the International Association for the Study of Lung Cancer (IASLC), researchers presented new data that revealed factors relating to race, gender, sexual orientation, and income continue to be significant barriers to those living with lung cancer. The press briefing is...
Outcomes and Patterns of Relapse in Pediatric Medulloblastoma
In a study reported in the Journal of Clinical Oncology, Kumar et al identified outcomes and patterns of relapse in pediatric patients with medulloblastoma. The investigators found that time to relapse and postrelapse survival was associated with subgroup and that the majority of relapses involve...
‘State of Tobacco Control’ 2021 Report Says Ending Tobacco Use Is Critical, Especially During the COVID-19 Pandemic
Even amid the COVID-19 pandemic, tobacco use remains a serious public health threat. In addition to tobacco-related death and disease, smoking also increases the risk of the most severe impacts of COVID-19. The American Lung Association has released its 19th annual “State of Tobacco Control”...
Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy
Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-reported outcomes with physician assessments of four common radiation-associated symptoms: pain, pruritus, ...
New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on screening in survivors’ later years. The guidelines, published today by Rachel A. Freedman, MD, MPH, and ...
New Clinical Calculator May Predict Recurrence Risk After Curative Colectomy for Colon Cancer
As reported in the Journal of Clinical Oncology, Weiser et al have developed a "third-generation" clinical calculator at Memorial Sloan Kettering Cancer Center (MSK), which incorporates molecular and clinicopathologic characteristics and provides an accurate prediction of disease recurrence...
FDA Pipeline: Priority Reviews for Immunotherapies in Gastric Cancers, Anal Cancer
The U.S. Food and Drug Administration (FDA) recently granted Priority Review to nivolumab as either adjuvant or first-line therapy in several types of gastric cancers, as well as to a novel PD-1 inhibitor for locally advanced or metastatic squamous cell carcinoma of the anal canal. The FDA also...
Prevalence of and Risk Associated With Breast Cancer Predisposition Genes: U.S. Population-Based Study
In a U.S. population-based, case-control study reported in The New England Journal of Medicine, Hu et al identified the prevalence of and risk associated with germline pathogenic variants in established and candidate breast cancer predisposition genes. Study Details The study involved 32,247 women...
Expect Questions About Adjuvant Chemotherapy for Older Women
Two recent studies found significant survival benefits for patients older than 70 years with surgically treated nonmetastatic triple-negative breast cancer who also received chemotherapy.1,2 The authors of both studies concluded that the findings support the consideration of chemotherapy for older...
Significant Survival Benefit From Chemotherapy for Older Women With Triple-Negative Breast Cancer
Women older than age 70 diagnosed with triple-negative breast cancer had significantly improved overall survival if they received adjuvant and/or neoadjuvant chemotherapy, according to an analysis of data from more than 16,000 women enrolled in the National Cancer Database. The estimated 5-year...
Chemotherapy Added to Local Therapy Improves Overall Survival in Older Women With Triple-Negative Breast Cancer
In a National Cancer Database analysis reported in The Lancet Oncology, Jennifer A. Crozier, MD, of the Division of Cancer Medicine, Baptist MD Anderson Cancer Center, Jacksonville, and colleagues found that receipt of neoadjuvant or adjuvant chemotherapy was associated with improved overall...
High Recurrence-Free Survival Rates in Rectal Cancer After Clinical Complete Response to Neoadjuvant Chemoradiotherapy
In a study reported in The Lancet Oncology, Laura M. Fernandez, MD, of Champalimaud Foundation, Lisbon, and colleagues found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained a clinical complete response to...
A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer
The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...
Osimertinib in Adjuvant Therapy for NSCLC With EGFR Mutations
On December 18, 2020, osimertinib was approved for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) with tumors with EGFR exon 19 deletions or exon 21 L858R mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 Supporting...
Venetoclax Added to Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues, the phase III BELLINI trial has shown that the addition of venetoclax to bortezomib/dexamethasone significantly prolonged progression-free survival in patients with...
Oral Azacitidine Is Noninferior to Placebo for Health-Related Quality of Life in AML
Health-related quality of life was sustained in patients taking oral azacitidine (also known as CC-486) compared with placebo in patients with acute myeloid leukemia (AML), according to results of the phase III QUAZAR AML-001 trial reported at the 2020 American Society of Hematology (ASH) Annual...
Adding Entinostat to Exemestane Fails to Overcome Aromatase Inhibitor Resistance in Advanced Breast Cancer
The histone deacetylase inhibitor (HDAC) entinostat, added to exemestane, failed to overcome endocrine therapy resistance in advanced breast cancer, according to the E2112 phase III trial conducted by the ECOG-ACRIN Cancer Research Group. Results showed that overall survival was not improved by the ...
Anastrozole vs Tamoxifen to Prevent DCIS Recurrence: Key Difference May Be Side-Effect Profile
If your patient were an older woman opting for hormonal therapy after surgically excised ductal carcinoma in situ (DCIS), which hormonal agent would you recommend for the prevention of disease recurrence: tamoxifen or anastrozole? According to long-term follow-up of the large, randomized IBIS...
Oral Taxanes Moving Forward in Metastatic Breast Cancer
Positive results have now been reported in phase III trials of two oral taxanes in the treatment of metastatic breast cancer. At the 2020 San Antonio Breast Cancer Symposium, treatment with tesetaxel and reduced-dose capecitabine resulted in an improvement in progression-free survival of about 3...
ASCO’s New Chief Medical Officer Plans to Tackle the Global Burden of Cancer and Disparities in Access to Care
In November, ASCO announced that Julie R. Gralow, MD, FACP, FASCO, will succeed Richard L. Schilsky, MD, FACP, FSCT, FASCO, as Chief Medical Officer (CMO) of the Society. Dr. Gralow will begin her new position on February 15, 2021. Dr. Gralow’s long relationship with ASCO dates back to 1995, when...
Relugolix for Advanced Prostate Cancer
On December 18, 2020, relugolix was approved for the treatment of adult patients with advanced prostate cancer. Relugolix is the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist to be approved in this setting.1,2 Supporting Efficacy Data Approval was based on findings in the...
ASCO Applauds Congress for Expanding Clinical Trial Access for Medicaid Beneficiaries
Statement By Monica M. Bertagnolli, MD, FACS, FASCO, Chair of ASCO “Congress took a giant step forward to reduce health disparities by expanding clinical trial access to more than 41.6 million Medicaid beneficiaries through passage of the bipartisan CLINICAL TREATMENT Act as part of its...
Selinexor in Relapsed or Refractory Multiple Myeloma
On December 18, 2020, selinexor was approved for use in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy.1,2 Selinexor received accelerated approval in 2019 for use in combination with dexamethasone for...
Margetuximab-cmkb for Previously Treated Metastatic HER2-Positive Breast Cancer
On December 16, 2020, margetuximab-cmkb (margetuximab) was approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.1,2...
New Study Finds Suspicious Lesions on Breast MRI in Neoadjuvant Setting Are Unlikely to Be Malignant
According a new study published by Eckstein et al in the American Journal of Roentgenology (AJR), new suspicious findings occurred in 5.5% of breast magnetic resonance imaging (MRI) examinations performed to monitor patients’ response to neoadjuvant therapy; none of these newly detected lesions...
